Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

CONCLUSIONS: -Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01583218. PMID: 27881569 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27881569?dopt=Abstract

Source: Circulation - November 13, 2016 Category: Cardiology Authors: Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators Tags: Circulation Source Type: research